. No correlation between HLA antigens and intolerances to drugs was found in seronegative patients, whereas in seropositive patients side effects to gold salts were associated with DR3. These results suggest that seropositive and seronegative RA have distinct HLA-DR associations, especially in disease of early onset, in addition to well established clinical differences.
The association of seropositive rheumatoid arthritis (RA) with the HLA system has been well established in several ethnic groups. Seropositive RA has been repeatedly shown to be associated with the HLA antigen DR4 in Caucasians,"' blacks, '1 12 Latin Americans,' and Japanese. ' Patients were tested for 49 alleles of four HLA loci. HLA A, B, and C groups were determined by the microcytotoxicity method using peripheral blood.'8 The DR specificities were determined by the standard technique described by Legrand and Dausset.t9 Unless otherwise stated, the x2 test was used for statistical analysis of the results.
Results

CLINICAL FINDINGS
Clinical data in seropositive and seronegative patients are summarised in Table 1 . Seronegative patients appeared to have an erosive disease less often than seropositive patients, despite similar treatment and disease duration (p<0-01). Extraarticular features of the disease were more frequent in seropositive than in seronegative patients, especially Raynaud's phenomenon, Sjogren's syndrome and rheumatoid nodules. The number of patients with at least one extra-articular feature was significantly (p<0O01) higher in seropositive than in seronegative patients. Tolerance to treatments was similar in the two groups.
HLA ANTIGENS
No significant difference was found between the frequencies of HLA A, B, and C antigens among seropositive or seronegative patients and controls. In particular the antigen B27 was found in 4% of seronegative RA patients and in respectively 8-7% and 10% of seropositive RA patients and controls. 4813 whereas others claimed that DR4 elevation was restricted to seropositive RA.1 3 6 These discrepancies are possibly due in part to differences in patient selection, as investigators have used different criteria for the diagnosis of seronegative RA. In our study particular attention was paid to selecting patients with a clinical profile suggesting RA and who were constantly seronegative by two methods, with a disease duration exceeding two years. In all cases the articular involvement was roughly symmetrical, with distal predominance, and other seronegative arthritides were carefully excluded. The population of patients we studied with seronegative rheumatoid arthritis clearly differed from seropositive patients and from controls. The frequency of HLA-DR4 was slightly elevated in seronegative patients in comparison with controls, but this increase is at the limit of statistical significance. In contrast the frequency of DR4 was very significantly elevated in seropositive patients as compared with controls (p<10-9)7 20 and with seronegative patients (p<0005). On the other hand, the frequency of DR1 antigen was clearly elevated in seronegative patients as compared with controls. Interestingly we have shown that DRl is associated with a slightly increased risk for seropositive RA when the data are corrected for the high DR4 frequency.7 Nevertheless, DR1 is significantly more frequent in seronegative patients as compared with seropositive patients (p<0-05).
DR1 has been previously reported to be elevated in seropositive RA in Jewish populations'4 and in Asian Indians,5 but to the best of our knowledge no mention has been made of its frequency in seronegative RA patients of these ethnic groups. In Caucasians the frequency of DR1 has been found to be elevated in seronegative RA in one study undertaken by Swiss investigators.9 Our results also suggest that DRI is associated with seronegative RA in Caucasians. The correlation we found between DR1 and an early onset of seronegative RA supports the hypothesis of a susceptibility factor associated with this antigen.
Finally, we were unable to demonstrate any association between HLA antigens and intolerances to drugs in our series of seronegative RA patients. Several 
